No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis

被引：0
|
作者：
Richard Nixon
Niklas Bergvall
Davorka Tomic
Nikolaos Sfikas
Gary Cutter
Gavin Giovannoni
机构：
[1] Novartis Pharma AG,Department of Biostatistics
[2] University of Alabama at Birmingham,undefined
[3] Queen Mary University of London,undefined
[4] Blizard Institute,undefined
[5] Barts and the London School of Medicine and Dentistry,undefined
来源：
Advances in Therapy | 2014年 / 31卷
关键词：
Disease-modifying therapies; Fingolimod; Indirect comparison; Multiple sclerosis; Neurology; Oral therapies;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1134 / 1154
页数：20
相关论文
共 50 条
  • [1] No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis
    Nixon, Richard
    Bergvall, Niklas
    Tomic, Davorka
    Sfikas, Nikolaos
    Cutter, Gary
    Giovannoni, Gavin
    ADVANCES IN THERAPY, 2014, 31 (11) : 1134 - 1154
  • [2] Oral therapies for treatment of relapsing-remitting multiple sclerosis in austria
    Guger, M.
    Enzinger, C.
    Leutmezer, F.
    Kraus, J.
    Kalcher, S.
    Kvas, E.
    Berger, T.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 179 - 179
  • [3] Oral disease-modifying therapies for relapsing-remitting multiple sclerosis
    Thomas, Rachel Hutchins
    Wakefield, Richard A.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (01) : 25 - 38
  • [4] Two new oral disease modifying therapies in relapsing remitting multiple sclerosis
    Lebrun, C.
    de Seze, J.
    REVUE NEUROLOGIQUE, 2014, 170 (12) : 721 - 722
  • [5] No evidence of disease activity and cognition in relapsing-remitting multiple sclerosis
    Alonso, R.
    Eizaguirre, B.
    Pita, C.
    Zavala, L.
    Silva, B.
    Marinangeli, A.
    Vanotti, S.
    Garcea, O.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 834 - 834
  • [6] Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
    Paolicelli, Damiano
    Manni, Alessia
    Iaffaldano, Antonio
    Trojano, Maria
    CNS DRUGS, 2020, 34 (01) : 65 - 92
  • [7] Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
    Damiano Paolicelli
    Alessia Manni
    Antonio Iaffaldano
    Maria Trojano
    CNS Drugs, 2020, 34 : 65 - 92
  • [8] Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies
    Zivadinov, Robert
    Keenan, Alexander J.
    Le, Hoa H.
    Ait-Tihyaty, Maria
    Gandhi, Kavita
    Zierhut, Matthew L.
    Salvo-Halloran, Elizabeth M.
    Ramirez, Abril Oliva
    Vuong, Vivian
    Singh, Sumeet
    Hutton, Brian
    BMC NEUROLOGY, 2024, 24 (01)
  • [9] Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity
    Juto, Alexander
    Fink, Katharina
    Al Nimer, Faiez
    Piehl, Fredrik
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 37
  • [10] Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; No evidence of rebound disease activity
    Juto, A.
    Fink, K.
    Al Nimer, F.
    Piehl, F.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 290 - 291
12345